[go: up one dir, main page]

WO2009020094A1 - 疎水性分子で修飾した抗体 - Google Patents

疎水性分子で修飾した抗体 Download PDF

Info

Publication number
WO2009020094A1
WO2009020094A1 PCT/JP2008/063959 JP2008063959W WO2009020094A1 WO 2009020094 A1 WO2009020094 A1 WO 2009020094A1 JP 2008063959 W JP2008063959 W JP 2008063959W WO 2009020094 A1 WO2009020094 A1 WO 2009020094A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrophobic molecule
antibody modified
antibody
immunoliposome
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/063959
Other languages
English (en)
French (fr)
Inventor
Koji Morita
Takako Niwa
Yuji Kasuya
Kimihisa Ichikawa
Hiroko Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to US12/672,861 priority Critical patent/US20110269942A1/en
Priority to JP2009526447A priority patent/JPWO2009020094A1/ja
Priority to EP08792163A priority patent/EP2184355A4/en
Publication of WO2009020094A1 publication Critical patent/WO2009020094A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本発明は、癌、自己免疫疾患または炎症性疾患に対して治療効果を有するイムノリポソーム製剤または疎水性分子修飾抗体に関する。すなわち、本発明は、デスドメイン含有受容体発現細胞にアポトーシスを誘導可能な抗体を構成成分とするイムノリポソームまたは疎水性分子修飾抗体に関する。
PCT/JP2008/063959 2007-08-09 2008-08-04 疎水性分子で修飾した抗体 Ceased WO2009020094A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/672,861 US20110269942A1 (en) 2007-08-09 2008-08-04 Antibodies modified with hydrophobic molecule
JP2009526447A JPWO2009020094A1 (ja) 2007-08-09 2008-08-04 疎水性分子で修飾した抗体
EP08792163A EP2184355A4 (en) 2007-08-09 2008-08-04 WITH A HYDROPHOBIC MOLECULE MODIFIED ANTIBODY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-208664 2007-08-09
JP2007208664 2007-08-09

Publications (1)

Publication Number Publication Date
WO2009020094A1 true WO2009020094A1 (ja) 2009-02-12

Family

ID=40341326

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/063959 Ceased WO2009020094A1 (ja) 2007-08-09 2008-08-04 疎水性分子で修飾した抗体
PCT/JP2008/063958 Ceased WO2009020093A1 (ja) 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063958 Ceased WO2009020093A1 (ja) 2007-08-09 2008-08-04 デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム

Country Status (8)

Country Link
US (2) US20100209490A1 (ja)
EP (2) EP2177230A4 (ja)
JP (2) JPWO2009020094A1 (ja)
KR (1) KR20100046185A (ja)
CN (1) CN101820913A (ja)
CA (1) CA2695991A1 (ja)
TW (2) TW200916477A (ja)
WO (2) WO2009020094A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209490A1 (en) * 2007-08-09 2010-08-19 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
JPWO2012093733A1 (ja) * 2011-01-07 2014-06-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
JP2020040983A (ja) * 2014-03-31 2020-03-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
JP2021512622A (ja) * 2018-02-06 2021-05-20 シアトル チルドレンズ ホスピタル ディー／ビー／エー シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ−ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
US11168109B2 (en) 2012-03-08 2021-11-09 Hanmi Science Co., Ltd. Process for preparation of physiologically active polypeptide complex
WO2022136939A1 (en) * 2020-12-21 2022-06-30 Samarth Zarad A method for preparation of a drug encapsulated liposome in an organic solvent emulsion
US11434271B2 (en) 2011-11-04 2022-09-06 Hanmi Science Co., Ltd. Method for preparing physiologically active polypeptide complex

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
EP2717856B1 (en) * 2011-05-10 2016-11-23 The Penn State Research Foundation Ceramide anionic liposome compositions
AU2012254842A1 (en) 2011-05-12 2013-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomes comprising polymer-conjugated lipids and related uses
EP3939572B1 (en) 2012-04-12 2024-03-27 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Ｇｓｋ３阻害剤と抗ｄｒ５抗体の組み合わせ
TWI585101B (zh) * 2012-11-16 2017-06-01 財團法人農業科技研究院 製備抗體Ｆ（ａｂ’）２片段之方法
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN105848649B (zh) 2013-11-01 2019-08-02 耶鲁大学 用于免疫疗法的模块化粒子
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
BE1022518B1 (fr) * 2014-03-12 2016-05-19 Glaxosmithkline Biologicals S.A. Formulation liposomale immunogene
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
CN107847444A (zh) * 2015-05-26 2018-03-27 通用医疗公司 脂质体纳米构建体及其制备和使用方法
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CA3056797A1 (en) * 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US20200230159A1 (en) * 2017-08-09 2020-07-23 The Regents Of The University Of Michigan Apoptosis-mimicking structures
CN107753434B (zh) * 2017-12-06 2019-11-05 西南交通大学 一种包载亲疏水性不同药物的载药脂质体及其制备方法与应用
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN111757941A (zh) * 2018-02-26 2020-10-09 Igm生物科学股份有限公司 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途
US20240108747A1 (en) * 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
IT202000004846A1 (it) * 2020-03-06 2021-09-06 Univ Degli Studi G Dannunzio Chieti Pescara Pro-drug innovativo micellare su backbone polimerico del Killer TNF-apoptosis induced ligand.
IT202000013042A1 (it) * 2020-06-01 2021-12-01 Univ Degli Studi G Dannunzio Chieti Pescara Sistema liposomiale con killer tnf-apoptosis induced ligand (killertrail), pro-apoptotico-direzionante.
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
US20230302154A1 (en) * 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
CN114150007B (zh) * 2021-12-14 2023-07-21 扬州大学 一种适用于家兔乳腺特异性表达去氨普酶的编码基因及其应用
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子
CN115181720B (zh) * 2022-07-27 2023-06-30 天津鸿宇泰生物科技有限公司 一种无血清培养基及其应用、一种cho细胞表达重组抗体的构建方法
CN116908335B (zh) * 2023-08-25 2025-09-26 遂成药业股份有限公司 一种高效液相色谱法检测卤代植物醇含量的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6972323B1 (en) * 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ES2366100T3 (es) * 1999-02-22 2011-10-17 Georgetown University Inmunoliposomas dirigidos mediante un fragmento de anticuerpo para la administración sistémica de genes.
DE10003653A1 (de) * 2000-01-28 2001-08-09 Thorsten Petrich Vektorkonstrukte zur gentherapeutisch vermittelten Radioiodtherapie entdifferenzierter und medullärer Schilddrüsen-Karzinome sowie nicht-thyreoidaler Tumore und ihrer Metastasen
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
EP1537858A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG Drug delivery vehicles and uses thereof
NZ553174A (en) * 2004-09-08 2010-03-26 Genentech Inc Methods of using death receptor ligands Apo2L/Trail and CD20 antibodies
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
MX2007013200A (es) * 2005-04-22 2008-03-24 Johnson & Johnson Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2.
US8361462B2 (en) * 2005-09-01 2013-01-29 National Research Council Of Canada Anti-apoptotic protein antibodies
EP2177230A4 (en) * 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HUWYLER J. ET AL.: "Brain drug delivery of small molecules using immunoliposomes.", PROC.NATL.ACAD.SCI.USA, vol. 93, no. 24, 1996, pages 14164 - 14169, XP002660204 *
KASAOKA S. ET AL.: "Stealth liposome for delivery system.", MEMBRANE, vol. 28, no. 3, 2003, pages 135 - 144, XP008036877 *
MATSUMURA Y. ET AL.: "DDS in cancer chemotherapy.", BIOTHERAPY, vol. 18, no. 4, 2004, Tokyo, pages 339 - 351, XP003000518 *
MILLSTEIN ET AL., NATURE, vol. 305, 61119, pages 537 - 539
MOTOKI K. ET AL.: "Preparation of anti TRAIL-R human antibodies from KM mouse and its application for cancer therapy.", GEKKAN MEDICAL SCIENCE DIGEST, vol. 31, no. 13, 2005, pages 530 - 534 *
OHTSUKI M. ET AL.: "Kandokusei o Shimesanai Shinkiko Fas Kotai HFE7A the 2nd report in vitro Apoptosis Yudo Koka", THE JAPANESE SOCIETY FOR IMMUNOLOGY GAKUJUTSU SHUKAI KIROKU, vol. 28, 1998, pages 293, 4 - A5-159 *
See also references of EP2184355A4

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110269942A1 (en) * 2007-08-09 2011-11-03 Daiichi Sankyo Company, Limited Antibodies modified with hydrophobic molecule
US20100209490A1 (en) * 2007-08-09 2010-08-19 Daiichi Sankyo Company, Limited Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
JPWO2012093733A1 (ja) * 2011-01-07 2014-06-09 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
US9309307B2 (en) 2011-01-07 2016-04-12 Seiko Epson Corporation Antibody against amyloid precursor protein signal peptide
US11434271B2 (en) 2011-11-04 2022-09-06 Hanmi Science Co., Ltd. Method for preparing physiologically active polypeptide complex
US11168109B2 (en) 2012-03-08 2021-11-09 Hanmi Science Co., Ltd. Process for preparation of physiologically active polypeptide complex
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
JP2020040983A (ja) * 2014-03-31 2020-03-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
JP2021512622A (ja) * 2018-02-06 2021-05-20 シアトル チルドレンズ ホスピタル ディー／ビー／エー シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ−ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
JP2024012513A (ja) * 2018-02-06 2024-01-30 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
WO2022136939A1 (en) * 2020-12-21 2022-06-30 Samarth Zarad A method for preparation of a drug encapsulated liposome in an organic solvent emulsion

Also Published As

Publication number Publication date
CN101820913A (zh) 2010-09-01
EP2184355A1 (en) 2010-05-12
TW200914064A (en) 2009-04-01
KR20100046185A (ko) 2010-05-06
WO2009020093A1 (ja) 2009-02-12
CA2695991A1 (en) 2009-02-12
US20110269942A1 (en) 2011-11-03
EP2177230A1 (en) 2010-04-21
JPWO2009020093A1 (ja) 2010-11-04
JPWO2009020094A1 (ja) 2010-11-04
US20100209490A1 (en) 2010-08-19
TW200916477A (en) 2009-04-16
EP2184355A4 (en) 2011-04-27
EP2177230A4 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
WO2009020094A1 (ja) 疎水性分子で修飾した抗体
CY2021027I1 (el) Σκευασματα αντισωματων anti-cd20
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
EP2379594B8 (en) Human cgrp receptor binding antibodies
LTC2170959I2 (lt) Antikūnai prieš žmogaus užprogramuotą mirties receptorių PD-1
ZA201001339B (en) Antibody targeting osteoclast-related protein Siglec-15
AU2008225994B2 (en) Monoclonal human tumor-specific antibody
EP2135075B8 (en) Whole blood assay
BRPI0814711A2 (pt) Conjunto diferencial com mecanismo de ajuste de pré-carga
BRPI0715544A2 (pt) Anticorpos que modificam doença cancerosas.
ZA200905062B (en) Cancerous disease modifying antibodies
NL2002173A1 (nl) Synthetic Aviation Fuel.
NL2001260A1 (nl) Tweeband-antenne.
ZA200905064B (en) Cancerous disease modifying antibodies
IL199666A0 (en) Cancerous disease modifying antibodies
NL2002066A1 (nl) Trailer.
AU2022203585B2 (en) Modified antibody constant region
ZA200907354B (en) Cancerous disease modifying antibodies
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
李世荣 Happy Birthday
HK1120559A (en) Cancerous disease modifying antibody 141205-02
HK1120561A (en) Cancerous disease modifying antibody 141205-05
HK1120562A (en) Cancerous disease modifying antibodies
AU2007321664A8 (en) Cancerous disease modifying antibodies
HK1134440A (en) Stable antibody formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792163

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009526447

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008792163

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12672861

Country of ref document: US